Siyu Xiang, Dong Kwon Yang, Jin-Shang Kim, Shang-Jin Kim
{"title":"花生四烯酸对硫乙酰胺所致大鼠肝肾损伤的改善作用。","authors":"Siyu Xiang, Dong Kwon Yang, Jin-Shang Kim, Shang-Jin Kim","doi":"10.1080/00498254.2025.2535407","DOIUrl":null,"url":null,"abstract":"<p><p>Arachidonic acid (ArA) is an essential omega-6 polyunsaturated fatty acid is crucial in various physiological processes and disease conditions. Nevertheless, the effects of arachidonic acid on liver and kidney damage are not well understood. Therefore, this study aimed to explore the beneficial role of ArA on liver and kidney injuries caused by thioacetamide (TAA) in rats, focusing on the associated hematological changes.The six groups, each consisting of 10 rats, are as follows; Control, 30 mg/kg ArA-treated, 20 mg/kg TAA-induced liver injury, ArA (10, 20, and 30 mg/kg)-pre-treated liver injury groups.The pre-treatment of ArA ameliorated histopathological injuries of hepatic and kidney tissues and hepatic dysfunction in TAA-treated rats. TAA increased hepatic and kidney injury serum biomarkers, otherwise, ArA significantly suppressed increased levels of these parameters and inhibited metabolic acidosis and dehydration due to TAA treatment. Besides, ArA effectively preserved protein and cholesterol metabolism against TAA-induced hepatic injury. ArA suppressed TAA caused ionic imbalance. Notably, the highest AA dosage (30 mg/kg) provided the most protective effects against TAA-induced liver and kidney damage.This study demonstrated that ArA effectively reduces liver and kidney injuries caused by TAA, indicating its potential as a promising preventive or therapeutic approach.</p>","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"517-525"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Arachidonic acid ameliorates the liver and kidney injuries induced by thioacetamide in rats.\",\"authors\":\"Siyu Xiang, Dong Kwon Yang, Jin-Shang Kim, Shang-Jin Kim\",\"doi\":\"10.1080/00498254.2025.2535407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Arachidonic acid (ArA) is an essential omega-6 polyunsaturated fatty acid is crucial in various physiological processes and disease conditions. Nevertheless, the effects of arachidonic acid on liver and kidney damage are not well understood. Therefore, this study aimed to explore the beneficial role of ArA on liver and kidney injuries caused by thioacetamide (TAA) in rats, focusing on the associated hematological changes.The six groups, each consisting of 10 rats, are as follows; Control, 30 mg/kg ArA-treated, 20 mg/kg TAA-induced liver injury, ArA (10, 20, and 30 mg/kg)-pre-treated liver injury groups.The pre-treatment of ArA ameliorated histopathological injuries of hepatic and kidney tissues and hepatic dysfunction in TAA-treated rats. TAA increased hepatic and kidney injury serum biomarkers, otherwise, ArA significantly suppressed increased levels of these parameters and inhibited metabolic acidosis and dehydration due to TAA treatment. Besides, ArA effectively preserved protein and cholesterol metabolism against TAA-induced hepatic injury. ArA suppressed TAA caused ionic imbalance. Notably, the highest AA dosage (30 mg/kg) provided the most protective effects against TAA-induced liver and kidney damage.This study demonstrated that ArA effectively reduces liver and kidney injuries caused by TAA, indicating its potential as a promising preventive or therapeutic approach.</p>\",\"PeriodicalId\":23812,\"journal\":{\"name\":\"Xenobiotica\",\"volume\":\" \",\"pages\":\"517-525\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Xenobiotica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00498254.2025.2535407\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Xenobiotica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00498254.2025.2535407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Arachidonic acid ameliorates the liver and kidney injuries induced by thioacetamide in rats.
Arachidonic acid (ArA) is an essential omega-6 polyunsaturated fatty acid is crucial in various physiological processes and disease conditions. Nevertheless, the effects of arachidonic acid on liver and kidney damage are not well understood. Therefore, this study aimed to explore the beneficial role of ArA on liver and kidney injuries caused by thioacetamide (TAA) in rats, focusing on the associated hematological changes.The six groups, each consisting of 10 rats, are as follows; Control, 30 mg/kg ArA-treated, 20 mg/kg TAA-induced liver injury, ArA (10, 20, and 30 mg/kg)-pre-treated liver injury groups.The pre-treatment of ArA ameliorated histopathological injuries of hepatic and kidney tissues and hepatic dysfunction in TAA-treated rats. TAA increased hepatic and kidney injury serum biomarkers, otherwise, ArA significantly suppressed increased levels of these parameters and inhibited metabolic acidosis and dehydration due to TAA treatment. Besides, ArA effectively preserved protein and cholesterol metabolism against TAA-induced hepatic injury. ArA suppressed TAA caused ionic imbalance. Notably, the highest AA dosage (30 mg/kg) provided the most protective effects against TAA-induced liver and kidney damage.This study demonstrated that ArA effectively reduces liver and kidney injuries caused by TAA, indicating its potential as a promising preventive or therapeutic approach.
期刊介绍:
Xenobiotica covers seven main areas, including:General Xenobiochemistry, including in vitro studies concerned with the metabolism, disposition and excretion of drugs, and other xenobiotics, as well as the structure, function and regulation of associated enzymesClinical Pharmacokinetics and Metabolism, covering the pharmacokinetics and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in manAnimal Pharmacokinetics and Metabolism, covering the pharmacokinetics, and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in animalsPharmacogenetics, defined as the identification and functional characterisation of polymorphic genes that encode xenobiotic metabolising enzymes and transporters that may result in altered enzymatic, cellular and clinical responses to xenobioticsMolecular Toxicology, concerning the mechanisms of toxicity and the study of toxicology of xenobiotics at the molecular levelXenobiotic Transporters, concerned with all aspects of the carrier proteins involved in the movement of xenobiotics into and out of cells, and their impact on pharmacokinetic behaviour in animals and manTopics in Xenobiochemistry, in the form of reviews and commentaries are primarily intended to be a critical analysis of the issue, wherein the author offers opinions on the relevance of data or of a particular experimental approach or methodology